AFP and hepatocellular carcinoma: For the differentiation of early-stage HCC from benign CLD in the algorithm development cohort, the AUC was highest with GAAD versus AFP or PIVKA-II alone (90.7% vs. 84.4% vs. 77.2%, respectively, Figure 3A).